Kodiak Sciences
Kodiak Sciences is a biopharmaceutical company focused on developing innovative therapeutics for retinal diseases, utilizing its proprietary Antibody Biopolymer Conjugate (ABC) Platform.
Overview of Kodiak Sciences
Kodiak Sciences develops novel therapeutics for high-prevalence retinal diseases. The company focuses on advanced drug development technologies, utilizing an Antibody Biopolymer Conjugate (ABC) Platform. Kodiak's approach is designed to create highly effective treatments for retinal conditions, aiming to improve patient outcomes.
Kodiak Sciences' Lead Investigational Medicine
Kodiak Sciences' lead investigational medicine is tarcocimab tedromer. This drug is targeted at treating retinal vascular diseases and is currently undergoing multiple Phase 3 studies. Specific conditions under investigation include diabetic macular edema and retinal vein occlusion. Tarcocimab tedromer exemplifies Kodiak's commitment to addressing significant unmet medical needs in ophthalmology.
KSI-501: Bispecific Antibody Development
KSI-501 is Kodiak Sciences' second investigational medicine. It is a bispecific antibody designed to target both VEGF and IL-6. This dual targeting approach aims to address diseases characterized by both vascular permeability and inflammation. KSI-501 signifies an advanced strategy in combating complex retinal diseases.
Kodiak Sciences Manufacturing Capabilities
Kodiak Sciences operates a custom-built commercial scale manufacturing facility named Ursus. This facility enables the large-scale production of the company's investigational medicines. The manufacturing capabilities at Ursus are crucial for supporting Kodiak's extensive clinical trial program and future commercial needs.
Kodiak Sciences Locations and Stock Information
Kodiak Sciences is headquartered in Palo Alto, California, with additional locations in Switzerland. The company is publicly traded on Nasdaq under the ticker symbol KOD. Kodiak's presence in key geographical areas supports its global research, development, and commercial operations.